Rebecca C. Arend, MD

Articles

Dr. Arend on Unmet Needs in Platinum-Resistant Ovarian Cancer

July 22nd 2020

Rebecca C. Arend, MD, discusses the unmet needs in of patients with platinum-resistant ovarian cancer.

Dr. Arend on FDA Approval of Frontline Bevacizumab in Ovarian Cancer

June 13th 2018

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the FDA approval of bevacizumab (Avastin) as a frontline treatment in combination with carboplatin and paclitaxel, followed by bevacizumab alone, for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Dr. Arend on Novel Combination Strategies in Gynecologic Cancer

February 17th 2018

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses novel combination strategies in gynecologic cancer.

Dr. Arend on the Rationale of Novel Combinations in Gynecologic Cancer

February 10th 2018

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the rationale behind novel combination strategies for patients with gynecologic cancer.

Dr. Arend Discusses Biomarkers in Endometrial Cancer

August 11th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses biomarkers in endometrial cancer.

Dr. Arend Discusses MSI Testing in Gynecologic Malignancies

August 10th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses microsatellite instability testing in patients with gynecologic malignancies.

Dr. Arend on the PORTEC-3 Trial for Endometrial Cancer

July 7th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the PORTEC-3 trial for patients with endometrial cancer.

Dr. Arend on Personalized Medicine for Endometrial Cancer

June 9th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses personalized medicine for patients with endometrial cancer.